Latest filings (excl ownership)
DEF 14A
Definitive proxy
18 Oct 24
PRE 14A
Preliminary proxy
7 Oct 24
8-K
Departure of Directors or Certain Officers
4 Oct 24
8-K
Oruka Therapeutics Announces $200 Million Private Placement
13 Sep 24
8-K
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5 Sep 24
425
Business combination disclosure
26 Aug 24
8-K
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
26 Aug 24
8-K
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
23 Aug 24
425
Business combination disclosure
16 Aug 24
8-K
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
16 Aug 24
425
Business combination disclosure
15 Aug 24
8-K
Entry into a Material Definitive Agreement
15 Aug 24
425
Business combination disclosure
9 Aug 24
425
Business combination disclosure
1 Aug 24
8-K
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
1 Aug 24
424B3
Prospectus supplement
1 Aug 24
10-Q
2024 Q2
Quarterly report
1 Aug 24
EFFECT
Notice of effectiveness
25 Jul 24
ARS
2023 FY
Annual report to shareholders
24 Jul 24
425
Business combination disclosure
9 Jul 24
8-K
Entry into a Material Definitive Agreement
9 Jul 24
425
Business combination disclosure
6 Jun 24
S-4
Registration of securities issued in business combination transactions
13 May 24
425
Business combination disclosure
25 Apr 24
8-K
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
25 Apr 24
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Departure of Directors or Certain Officers
23 Apr 24
8-K
Departure of Directors or Certain Officers
4 Apr 24
425
Business combination disclosure
3 Apr 24
8-K
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
3 Apr 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
8-K
Departure of Directors or Certain Officers
6 Feb 24
8-K
ARCA biopharma Announces 2023 Financial Results
1 Feb 24
10-K
2023 FY
Annual report
1 Feb 24
8-K
Departure of Directors or Certain Officers
31 Jan 24
ARS
2022 FY
Annual report to shareholders
19 Dec 23
DEFA14A
Additional proxy soliciting materials
19 Dec 23
Latest ownership filings
SC 13G
FMR LLC
7 Oct 24
SC 13D/A
Fairmount Funds Management LLC
13 Sep 24
4
Peter Evan Harwin
13 Sep 24
SC 13D
Fairmount Funds Management LLC
6 Sep 24
3
Peter Evan Harwin
6 Sep 24
3
Cameron Turtle
6 Sep 24
3
Samarth Kulkarni
6 Sep 24
3
Carl Dambkowski
6 Sep 24
3
KRISTINE M BALL
6 Sep 24
3
Paul T Quinlan
6 Sep 24
3
Joana Goncalves
6 Sep 24
3
Arjun Agarwal
6 Sep 24
3
Lawrence Otto Klein
6 Sep 24
4
Jacob Ma-Weaver
30 Aug 24
4
Change in insider ownership
20 Aug 24
4
Change in insider ownership
26 Jul 24
4
Change in insider ownership
12 Jul 24
3
Initial statement of insider ownership
12 Jul 24
SC 13G/A
JANUS HENDERSON GROUP PLC
5 Jul 24
SC 13G
Venrock Healthcare Capital Partners III, L.P.
29 Apr 24
SC 13G
Allostery Investments LP
15 Apr 24
SC 13G
JANUS HENDERSON GROUP PLC
11 Apr 24
SC 13G
Avidity Partners Management LP
9 Apr 24
SC 13G/A
Western Standard LLC
5 Apr 24
SC 13D
Adage Capital Management, L.P.
5 Apr 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
Jacob Ma-Weaver
31 Jan 24
4
Anders D Hove
31 Jan 24
4
DANIEL J MITCHELL
31 Jan 24
4
James P Flynn
31 Jan 24
4
ROBERT E CONWAY
31 Jan 24
4
Linda Grais
31 Jan 24
4
Raymond L. Woosley
31 Jan 24
SC 13G
Western Standard LLC
11 Sep 23
SC 13G/A
BML Investment Partners, L.P.
8 Feb 23
4
Jacob Ma-Weaver
19 Dec 22
4
Raymond L. Woosley
19 Dec 22
4
DANIEL J MITCHELL
19 Dec 22
4
Linda Grais
19 Dec 22
4
Anders D Hove
19 Dec 22